Faron Pharmaceuticals Oy
FARN.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | – | – | – | – |
| R&D Expenses | £12 | £19,542 | £20,730 | £17,369 |
| G&A Expenses | £6,683 | £8,706 | £7,498 | £9,876 |
| SG&A Expenses | £6,929 | £9,052 | £7,498 | £9,876 |
| Sales & Mktg Exp. | £246 | £346 | £0 | £0 |
| Other Operating Expenses | -£6,922 | -£26 | -£803 | -£6,137 |
| Operating Expenses | £19 | £28,568 | £27,425 | £21,108 |
| Operating Income | -£19 | -£28,568 | -£27,426 | -£21,108 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -£7 | -£2,376 | -£1,304 | -£70 |
| Pre-Tax Income | -£26 | -£30,944 | -£28,730 | -£21,178 |
| Tax Expense | £0 | £0 | £1,304 | £16 |
| Net Income | -£26 | -£30,944 | -£28,730 | -£21,194 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.34 | -0.38 | -0.29 |
| % Growth | 99.9% | 10.5% | -31% | – |
| EPS Diluted | -0 | -0.34 | -0.38 | -0.29 |
| Weighted Avg Shares Out | 88,518 | 78,641 | 66,764 | 61,317 |
| Weighted Avg Shares Out Dil | 88,518 | 78,641 | 66,764 | 61,317 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £2 | £96 | £165 |
| Interest Expense | £4 | £0 | £1,400 | £235 |
| Depreciation & Amortization | £0 | £197 | £300 | £135 |
| EBITDA | -£18 | -£28,371 | -£27,057 | -£20,973 |
| % Margin | – | – | – | – |